+450.5%
AAOI vs MRNA
+554.4%
-103.9%
-92.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.0% | +5.4% | -3.4% | +1.5% |
| 7D | -0.2% | -1.1% | +0.9% | -0.1% |
| 30D | -23.7% | +126.1% | -149.8% | -36.7% |
| 3M | -39.0% | +190.0% | -229.0% | -52.4% |
| 6M | -17.0% | +157.2% | -174.3% | -34.3% |
| YTD | +202.2% | +388.2% | -186.0% | +107.9% |
| 1Y | +292.4% | +467.0% | -174.6% | +162.0% |
| 3Y | +804.4% | +36.1% | +768.3% | +642.6% |
| 5Y | +1,318.0% | -68.0% | +1,386.0% | +1,218.5% |
| All | +450.5% | +554.4% | -103.9% | +291.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling